Background:Endometrial cancer is associated with changes in blood cell counts and with high levels of inflammatory markers, thus reflecting the tumor’s impact on various biological processes and suggesting their potential as biomarkers for endometrial cancer diagnosis, prognosis, and treatment response. The neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in peripheral blood sampled preoperatively from patients have been reported to be independently associated with the prognosis of different types of malignancies.Objectives:This study aimed to compare several blood markers—red blood cells, white blood cells, platelet parameters, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, C-reactive protein, and fibrinogen—in patients with benign or malignant endometrial tumors.Material and methods:Our retrospective study included 670 patients (192 diagnosed with endometrial cancer and 478 with endometrial hyperplasia), and we compared the serological parameters discussed above with those sampled the day before surgery.Results:Analysis of complete blood count indices revealed no significant differences in red blood cell or total white blood cell parameters between the endometrial cancer group and the endometrial hyperplasia group. However, a distinct pattern emerged in the white blood cell differential. The endometrial cancer group showed a statistically significant decrease in lymphocyte count compared with the endometrial hyperplasia group. In contrast, the endometrial cancer group showed significantly higher mean platelet counts and increased mean platelet volume compared with controls. Furthermore, the endometrial cancer group demonstrated a marked inflammatory response, as evidenced by significantly elevated levels of C-reactive protein, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio compared with the endometrial hyperplasia group.Conclusions:The current research revealed statistically significant differences in multiple serological biomarkers between the two groups. These findings support the initial hypothesis regarding the potential utility of these biomarkers in endometrial cancer diagnosis, prognosis, and treatment response, highlighting the existence of biomarkers affordable for analysis under any health system, regardless of the country’s level of development.
背景：子宫内膜癌与血细胞计数的变化及炎症标志物水平升高相关，这反映了肿瘤对多种生物学过程的影响，并提示这些指标可能作为子宫内膜癌诊断、预后及治疗反应的生物标志物。已有研究报道，术前采集的患者外周血中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及单核细胞与淋巴细胞比值与多种恶性肿瘤的预后独立相关。 目的：本研究旨在比较良性与恶性子宫内膜肿瘤患者的多种血液标志物——红细胞、白细胞、血小板参数、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、单核细胞与淋巴细胞比值、C反应蛋白及纤维蛋白原。 材料与方法：本回顾性研究纳入670例患者（192例诊断为子宫内膜癌，478例为子宫内膜增生），比较了上述血清学参数与术前一天采集的样本数据。 结果：全血细胞计数指标分析显示，子宫内膜癌组与子宫内膜增生组在红细胞或总白细胞参数上无显著差异。然而，白细胞分类计数呈现出明显差异。与子宫内膜增生组相比，子宫内膜癌组的淋巴细胞计数在统计学上显著降低。相比之下，子宫内膜癌组的平均血小板计数和平均血小板体积均显著高于对照组。此外，子宫内膜癌组表现出明显的炎症反应，具体表现为C反应蛋白、纤维蛋白原、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及单核细胞与淋巴细胞比值均显著高于子宫内膜增生组。 结论：当前研究揭示了两组间多种血清学生物标志物存在统计学显著差异。这些发现支持了最初的假设，即这些生物标志物在子宫内膜癌的诊断、预后及治疗反应中具有潜在应用价值，并强调了存在适用于任何卫生体系（无论国家发展水平如何）且经济可及的生物标志物。
Clinical Correlations between Serological Markers and Endometrial Cancer
肿瘤(癌症)患者之家